Our findings establish CHIP, particularly TET2 mutations, as an independent risk factor for worsened CAD outcomes, providing novel insights into its pathophysiological role in inflammation, lipid metabolism, and plaque instability. This evidence concerns the gene STUB1 and coronary artery disorder.